Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR vs Standard Care for Oligometastatic Tumors
NCT06556550Phase 3Recruiting
- Start
- May 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms). Primary endpoints: Progression-free survival at 3 years and Time before the current drug line change at 3 years. Started May 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06556550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556550.